Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Health‐related quality of life ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Healing of osteonecrosis - improvement ('healed' or 'improved' vs 'unchanged' or 'worse') · People with BRONJ (mean age ~66 years; most treated with bisphosphonates for cancer (multiple myeloma, breast cancer) or osteoporosis)
Hyperbaric oxygen therapy plus standard care (surgery, antibiotics,… showed no clear difference in healing of osteonecrosis - improvement ('healed' or 'improved' vs… compared with standard care alone (surgery, antibiotics, oral rinse); GRADE not reported.
5 findings from 1 review
RR 1.75 [0.51, 5.98]
1 study · 18 participants
GRADE not reported
RR 1.78 [0.97, 3.28]
1 study · 46 participants
GRADE not reported
RR 1.94 [1.01, 3.74]
1 study · 45 participants
Very low
Show 2 more findings
Healing of osteonecrosis - healed ('healed' vs 'improved', 'unchanged' or 'worse') · People with BRONJ (mean age ~66 years; most treated with bisphosphonates for cancer (multiple myeloma, breast cancer) or osteoporosis)
Hyperbaric oxygen therapy plus standard care (surgery, antibiotics,… showed no clear difference in healing of osteonecrosis - healed ('healed' vs 'improved',… compared with standard care alone (surgery, antibiotics, oral rinse); GRADE not reported.
5 findings from 1 review
RR 1.56 [0.77, 3.18]
1 study · 46 participants
GRADE not reported
RR 1.00 [0.25, 4.00]
1 study · 18 participants
GRADE not reported
RR 0.95 [0.44, 2.04]
1 study · 40 participants
GRADE not reported
Show 2 more findings
Pain · People with BRONJ (mean age ~66 years; most treated with bisphosphonates for cancer (multiple myeloma, breast cancer) or osteoporosis)
1 finding from 1 review
Adverse effects · People with BRONJ (mean age ~66 years; most treated with bisphosphonates for cancer (multiple myeloma, breast cancer) or osteoporosis)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Quality of life · People with BRONJ (mean age ~66 years; most treated with bisphosphonates for cancer (multiple myeloma, breast cancer) or osteoporosis)
1 finding from 1 review
Non‐fatal PE (3 to 12 months) · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in non‐fatal PE (3 to 12 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
All‐cause mortality (3 to 6 months) · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in all‐cause mortality (3 to 6 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Major bleeding · participants with diagnosed DVT
Oral factor Xa inhibitors leads to lower major bleeding (3 to 12 months) compared with conventional anticoagulation (high certainty).
1 finding from 1 review
Recurrent VTE · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in recurrent VTE (3 to 12 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Recurrent DVT (3 to 12 months) · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in recurrent DVT (3 to 12 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Fatal PE (3 to 12 months) · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in fatal PE (3 to 12 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral factor Xa inhibitors showed no clear difference in all‐cause mortality compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Major bleedinge · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral factor Xa inhibitors showed no clear difference in major bleedinge compared with conventional anticoagulation (low certainty).
1 finding from 1 review
Health‐related quality of life · patients with a pulmonary embolism, confirmed by standard imaging techniques
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent PE · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral factor Xa inhibitors showed no clear difference in recurrent PEa compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Recurrent VTEc · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral factor Xa inhibitors showed no clear difference in recurrent VTEc compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
DVTd · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral factor Xa inhibitors showed no clear difference in DVTd compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review